Get started

Healthcare

BFLY Price Target $20BFLY Current Price $12.20 Price Target $20 I like BFLY here, as it has over $500 million in cash following its merger with Longview, and I like that it is fully expected to be cash-flow positive by 2024.Revenue increased 40.0% to $16.5 million in Q2 2021 from $11.8 million in Q2 2020. The revenue can be traced to both product and subscription revenues. Product revenue increased 30.3% to $13.0 million from $10.0 million last year. That is solid. The company is focused heavily on improving subscriptions, and it is translating to sales. Subscription revenue increased 94.3% to $3.5 million from $1.8 million last year. I see this line of revenue growing sizably in the coming quarters as it becomes a bigger focus of the company. With a half of billion in cash BFLY has significant funds to continue growing their customer base with their innovative cost cutting products. Their Butterfly IQ+ is a handheld ultrasound which is cutting the cost of ultrasounds by over 90%, this opens up the opportunity for the company to expand to developing countries with this amazing cost cutting innovation.
NYSE:BFLYLong
by Value-Invest
Growing Stocks to Watch in the Chinese Market: (NFH:NYSE)● The regulatory and other uncertainties in the Chinese market directly impact sectors like fintech, gaming and education. ● Winners will be companies that have benefited from the regulatory change or captured the newly emerging opportunities. ● We are bullish on Hailiang Education, WiMi Hologram Cloud, 360 DigiTech and New Frontier Health and will explain the reasons in this article. New Frontier Health (NFH:NYSE) New Frontier Health, the parent company of one of Asia's largest high-end medical service providers – United Family Healthcare, offers customized healthcare services. The company includes over 600 full-time doctors from 25 countries, over 1,000 part-time specialists and over 1,000 nurses. In early 2020, the COVID-19 outbreak affected the company's business. resulting in a lower income level at the pediatric and O.B departments that year. However, it is clear now that New Frontier is recovering from the pandemic with growing revenue, narrowing net losses and upping EBITDA, while it has been dropping operating expenses. It is proven that the overall operational efficiency and profitability have been improved. In February of 2021, the buying party of New Frontier made a privatization offer to buy back all the common stocks at USD 12 per share, to delist the company from the NYSE. The next step will be the IPO on the Hong Kong bourse. Aging China presents new growth opportunities for private healthcare companies. the planned exchange 'migration' may also help the company to overcome undervaluation in the US capital market and gain more recognition from the local investors in Hong Kong. For the full article with the charts, please visit the original link.
NLong
by EqualOcean
Ok. Pfizer is going NUTS! 🚀🚀🚀Nothing is more profitable than fear. I think Pfizer profits have doubled by Q2 and it's getting even crazier, way crazier. The whole west is throwing money at them with government and most urbanites in total fear. They don't even care how much it costs. Destroy a country? Lose 10% of GDP? They don't care, just name your price. Take AMZN for example. Went vertical, retested ATH, then to the moon. In the short term (2-3 months or even less) it can be really profitable. Who cares if Pfizer gets destroyed by crowds after we made our money? It won't happen overnight (probably). Here it's different from Amazon there is no reason for the company to trend for years (for now). It's really short term with the hysterical fear pushing profits to incredible levels. Share prices have a tendency to retrace after breaking ATH, once again, profitable in the short term. I'm not stock trader but here it is really juicy. I'm sure there are similar examples? Price just going vertical... 1999 bubble for sure... I am not experienced enough but I assume it always or almost always retests ATH I'm sure it's possible Pfizer just goes vertical, the noob bagholding investors as always will want to greedily snatch their profits the moment they see some green and cause a pullback but euphoria could absorb the selling. Something like that.... Consolidation... And again... Got to check my favorite example Moderna for 2 years has simply been in a beautiful trend, a work of art. And it is up more than 1000% since 2020. Some to compare moderna to: Other cool trends
NYSE:PFELong
by MrRenev
4
Whatever WORX Right?WORX stock tested a key FIb level on Wednesday being the 50 fib line after plotting the top anchor at the recent high the first time WORX busted above the 50 fib. Before this latest round of testing, the last time WORX reached this key level it was rejected heavily. A few weeks ago, the company announced that it had regained compliance with the NASDAQ listing requirements. At the same time, it announced that Tim Hannibal, current COO, would become the new CEO. He stated that “over the last 10-15 years, technology within the healthcare industry has evolved both in cost and complexity. Unfortunately, the technology which was implemented within different hospital departments and with disparate objectives has failed to provide the promised advancements.” As a leader in providing software to healthcare institutions, there is a clear benefit that Scworx could gain from the pandemic’s current state and the ending of Covid-19. With all of this in mind, is WORX stock worth keeping an eye on? Quote source and read more: 4 Epicenter Penny Stocks You Need to Know About in 2021
NASDAQ:WORX
by PennyStocks101
Are Covid Stocks Coming Back?If there is any hope for the S&P right now it may very well come from the healthcare sector with mega blue chip Johnson & Johnson. JNJ has managed to put in consecutive higher highs and higher lows on the weekly, and now also is confirming support on the .618 fibonacci level at $165.40. However, there appears to still be much selling pressure at just above $168, so don't be surprised if we continue to see consolidation for another a week or two before getting the confirmed breakout above our red resistance line at the aforementioned $168 price level. If resistance at this level is broken, we will be seeing a possible retest of blue sky all time highs for the healthcare giant JNJ. In the meantime, I am liking the idea of small longs along the .618 ($165.40) area as long as the upward sloping green trend is not violated.
NYSE:JNJLong
by TradeVibez
BFLY Should Hold SupportBFLY Current Price $12.75 Price Target $20 This company is a fairly valued (5x PE) innovative healthcare company. Butterfly Networks is cutting the cost of ultrasounds by 90% with their handheld device, the new ultrasound platform uses a semiconductor rather than a crystal based sound wave. They are targeting emerging markets with this amazing cost cutting innovation. It hasn’t been a better time to buy BFLY in quite some time as BFLY is now trading on crucial support around $12.50. I think we hold this support line and trade up to the top line of resistance around $15 within the next couple months then we should move up to $20 in the coming months.
NYSE:BFLYLong
by Value-Invest
1
BFLY Price Target $25BFLY Current Price $14.36 Price Target $20 $10c 10/15 ($470, 3% till breakeven) We have been in BFLY since $10. This company is a fairly valued (5x PE) innovative healthcare company. Butterfly Networks is cutting the cost of ultrasounds by 90% with their handheld device, the new ultrasound platform uses a semiconductor rather than a crystal based sound wave. They are targeting emerging markets with this amazing cost cutting innovation. We saw insiders buy over 2 million worth of shares earlier this month, which signifies confidence of the business within the company. This is a long term hold for me!
NYSE:BFLYLong
by Value-Invest
CloudMD $DOC.V - Months of selling and consolidation done?CloudMD has been under selling pressure for months now. Today it closed its Vision Pros Acquisition and is expected to close its largest acquisition - Oncidium this month as well. The company can boast a 125-130mil revenue run rate. Vision Pros adds 22 mil in rev and 10% EBITDA margins to the bottom line for CloudMD. I have a position in this company. It has not been an easy 3-4 months. The rest of the week will prove out if this was a one and done green day yesterday or if buyers are serious and ready to take control again. PT on DOC is $3.96. Was a "top pick" on Bloomberg MarketCall June 23rd. At some point the market is going to start respecting that revenue and positive EBITDA that the company is set to report for this full fiscal year. currently trading at 3x sales. This should definitely be on the watchlist now. Look to see Buyers control Price around the 2SD Cross as highlighted. DCA approach the play here. DOC.V is a long hold for myself. Hope the chart and thoughts help. Please do you own DD and follow your own trading rules. Cheers, Luke
DLong
by LeBelleChart
3
Medifast bullish trend line crossA Bullish Trend Line Cross Medifast has just completed a bullish upward move across a resistance trend line. I've purchased a July 16 call option and also bought some shares. I'm hoping it will move up as decisively as it recently moved down, hitting $290 by early July. For confirmation, look for a candle close above the trend line today. If price closes the day below the trend line, this signal is invalidated. Fundamentals I estimate Medifast's forward P/E at about 17, forward P/S at about 2, and forward dividend yield at about 2.33%. P/FCF is about 18. These numbers are pretty middle of the road. But where Medifast really shines is its growth rate. Over a five-year period, it has averaged 7-8% sales and earnings growth and 11% free cash flow growth. Arguably the price multiples are low given that growth rate. S&P Global gives Medifast a 74/100 average fundamentals score. I give Medifast a 4/6 for its earnings outlook. It got a minor downward revision to its earnings forecast around June 1, which is why the price took a dive. But this massive downward move was a huge overreaction relative to the size of the forecast revision, and I expect MED to snap back to around the $300 level. Sentiment Medifast has a 9.9/10 analyst summary score, up 0.4 points over the last 30 days. The put/call ratio is somewhat bearish, at 1.6, but I expect that to improve after the bullish trend line cross. Technicals are net bullish, and I estimate about 23% risk/reward ratio here as long as it holds support at 261. There's 35% upside to the average analyst price target.
NYSE:MEDLong
by ChristopherCarrollSmith
13
RGLS Showing Interesting LevelsRGLS continues pivoting around that 618 Fib line. Overall, it has held a clear uptrend despite the pullback. Trend line lines up almost perfectly with the latest higher lows put in. RNA companies remain a focus. In this case, it's not covid but kidney diseases. "In mid-May, Regulus Therapeutics announced an incremental update of its autosomal dominant polycystic kidney disease program. The CEO of the company, Jay Hagan said, “As previously reported, the ninth and final patient was trending well at the end of the dosing period and saw their polycystin levels continue to rise until study completion, twenty-eight days after the last dose. This pattern was generally consistent across the first cohort and further enhanced the overall mean changes from baseline for both biomarkers." PLUS upcoming presentation of RGLS4326 for the treatment of ADPKD at the PKD Connect Conference 2021 this Friday (6/25) could be something to keep in mind right now too. Quote Source: 7 Hot Penny Stocks to Watch That Are Trending Right Now
NASDAQ:RGLS
by PennyStocks101
Centene, I was neglecting you but now I see you in your splendorThe algorithmic advisor Market Miracle is suggesting for some days a LONG entry on the title CENTENE $CNC The company that is basically a Healthcare is in charge of the US-wide care of patients with and without health coverage. The signals that I have been provided on Centene these days did not have a particularly explosive aspect for which for my fault they have been neglected but analyzing the company more from the fundamentals it emerges that Centene is really in excellent health and ripe for a possible growth slow but steady for a long time. In fact, according to some sites that I use as a reference to find data on companies is far below its fair value, has no particular alerts if not a debt situation in which the covid has contributed a lot but hopefully over time should be reduced. From a graphic point of view we are already at the peak and between an overbought and the other always manages to climb a step higher than the index of its strength. Analyzing Miracle Viewer, the indicator that tries to identify the positions of the big players of marked, we see that they are returning investments by the institutions so the title could accelerate its rise. From a graphical point of view in the very short I expect a climb like the one described in the chart but I imagine there will be new and future updates very soon. I will take a position on the title as soon as possible. This idea is based on a signal generated by the advisor Marketmiracle, down on this page you will find the link to the page of signals of the advisor that you can see for free without any cost or registration
NYSE:CNCLong
by MarketMiracleAdvisor
AVTR -AvantorHealth Care : Life Sciences Tools & Services | Mid Cap Growth Avantor, Inc. is a global provider of mission critical products and services. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables includes chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation includes filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. One of IBD's BOUT ETF breakout holdings EPS % Chg (Last Qtr)106% Joined IBD 50 06-09-21 Entry 32.89/ stop 30.63 1R 2.26 1R PRICE 35.15 2R PRICE 37.41 3R PRICE 39.67 Entering 1/2 position. Just my own observations. Educational purposes and not financial advice. As always, do your own research.
NYSE:AVTRLong
by Tea-Trades
2
Mirum Insane Catalyst Play*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Mirum Pharmaceuticals: My team has been reviewing Mirum Pharmaceuticals for close to two months, and despite its poor performance in the past month it remains one of top picks for the month of June. Mirm is to present data for their assets which target rare liver diseases on June 3rd 2021. Its recent price rejection at $15.85 increases our confidence in this play. There have been jumps from this zone up to $20-26, so we expect a similar pattern to repeat. Next week's data results simply have to be adequate enough to regain investor attention. My team is especially confident in the risk-to-reward ratio of this trade. We entered today @$16.30. Short term take profit @$20.00 Long Term take profit @$30.00 Stop Loss @$14.90 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney